ArticleFrontiers in immunology2026
Serotype-specific tropism of adeno-associated viruses in dorsal meningeal lymphatic vessels via intra-cisterna magna delivery.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meningeal lymphatic vessels (mLVs) in the brain acts as the regulator that eliminates harmful macromolecules in post-cerebrospinal fluid (CSF) and facilitates immune cell migration to cervical lymph nodes. However, it still poses challenges on the investigation of separated mLVs biological functions because of its unique anatomical position on the dorsal skull. Studies have been revealed that the recombinant adeno-associated virus (rAAV)2/1 serotype can be recognized as delivery vehicles targeting mLVs, which further can be exploited to evaluate mLVs biological functions. Nevertheless, the characteristics for infection of rAAV2/1 needs more investigations. Methods: In the present study, 8-week-old male C57BL/6 mice were selected, and rAAVs of different serotypes were injected either into the cisterna magna filled with CSF or via lateral ventricle injection, to compare the specificity of distinct rAAV serotypes for infecting mLVs. Results: Through intracisternal magna delivery, rAAV2/1-CMV-EGFP exhibited selective mLVs targeting with sustained fluorescence intensity. Additionally, rAAV2/5-CMV-EGFP, rAAV2/8-CMV-EGFP, rAAV2/9-CMV-EGFP, rAAV2/BR1-CMV-EGFP, and rAAV2/PHPeB-CMV-EGFP also showed the same trend. Significantly, rAAV2/9-CMV-EGFP infectivity via the injection in medullary cisterna induces EGFP expression in mLVs that is dose-dependent. However, at higher viral doses (≥1×10 Conclusion: This study revealed the characteristics of diverse rAAV serotypes in mLVs research, suggesting that rAAVs can be regarded as a powerful and safe gene therapy tool for unveiling the role of mLVs under neuroinflammatory conditions or central nervous system (CNS) disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.